Radiation Therapy
53
15
20
17
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
1.9%
1 terminated out of 53 trials
94.4%
+7.9% vs benchmark
9%
5 trials in Phase 3/4
6%
1 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (53)
CAIX PET/ CT Guided Radiation Therapy in CcRCC.
3D Specimen Maps for RT Planning
Immunotherapy And Palliative Radiotherapy Combined In Patients With Advanced Malignancy
Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment
Activity Coaching During Pelvic Radiation Therapy
Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries
18F-FLUC PET/MR in Patients With Brain Mets
Locally Optimised Contouring With AI Technology for Radiotherapy
SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer
Intraoral Hypothermia Device for Preserving Taste During Radiation
Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet
Effectiveness of Virtual Reality (VR) in the Management of Anxiety for Patients Undergoing Radiotherapy
Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial
Improving Outcomes for Older Adults Undergoing Radiation Therapy
Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial
Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy
Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases
SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy
Adjuvant Chemotherapy for High Malignant Prostate Cancer